MOLN

NASDAQ 已收盘

Molecular Partners AG

4.20 USD
+0.18+4.48%
盘后 3.93 -6.43%
2026-09-15
市值
$150.12M
市盈率
EPS
-1.68
股息率
52 周区间
3.53 – 5.36
成交量
3.67K
Beta
0.69
目标价
10.55
52W 低 3.5352W 高 5.36
价格走势

公司简介

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...